Current Edition

Upcoming Events


NBE to Present Late-Breaking Abstract on Lead ADC Program NBE-002 (ROR1) at the AACR Annual Meeting

BASEL, Switzerland, March 13, 2019 / B3C newswire / — NBE-Therapeutics AG, a biopharmaceutical company developing next-generation, immune-stimulatory antibody-drug conjugates (iADCs) for improved cancer therapy, today announces that it will present a late-breaking abstract at the Annual Meeting of the American Association for Cancer Research (AACR) to be held from March 29 – April 3, 2019 in Atlanta, Georgia, U.S. (abstract number LB-197). The title of the late-breaking abstract selected by AACR is: “NBE-002, an anthracycline-based immune-stimulatory antibody drug conjugate (iADC) targeting ROR1 for the treatment of triple-negative breast cancer”. The abstract discusses the profound in vivo anti-tumor efficacy of NBE’s lead iADC program, NBE-002, in preclinical, patient-derived triple-negative breast cancer models over a wide range of ROR1 expression levels, as well as the potent immune-oncology function of NBE’s iADC platform. A poster will be presented in the Immunology session at AACR on:

Date: Tuesday April 2, 2019

Time: 8:00am to 12:00pm

Abstract number: LB-197

The NBE team will present the detailed data to industry stakeholders at a workshop from 06:30 to 8:00 p.m. on the same day. Participation in the event is by invitation only.

“This late-breaking abstract shows the continuous innovation at NBE-Therapeutics and is an exciting demonstration of the best-in-class long-lasting anti-tumor efficacy of NBE-Therapeutics’ iADC platform in one of oncology`s most challenging fields of triple-negative breast cancer”, said Roger Beerli, NBE`s Chief Scientific Officer.

NBE develops next-generation iADCs based on its proprietary, site-specific SMAC-Technology™ and a novel highly potent anthracycline-based toxin platform. NBE has the objective to develop first- and best-in-class ADC product candidates against tumor targets in cancer indications of high unmet medical need. Its first lead candidate NBE-002 is forecasted to enter clinical trials in 2020.